Payment overview · 2025
General Payments
$35,869.78
63 reported records · 10 companies
Healthcare provider profile · identity verified
Daniel Michael Englert, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ORLEANS, LA · NPI 1891094793
Verified facts
What the public records show
CMS Open Payments records show Daniel Michael Englert, MD received $35,869.78 in general payments during 2025 across 63 reported records.
Amgen Inc. accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Tymlos.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $18,304.42 | 51.0% | 25 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $11,221.69 | 31.3% | 23 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $6,029.98 | 16.8% | 6 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.87 | 0.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.61 | 0.1% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $51.86 | 0.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.90 | 0.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.17 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.57 | 0.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.71 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,462.00 | 15 |
| Food and Beverage | $2,021.92 | 32 |
| Travel and Lodging | $1,210.86 | 15 |
| Consulting Fee | $175.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17,913.04 | 22 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $7,528.45 | 18 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $6,029.98 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $122.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $53.61 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $51.86 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 36 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 94 |
| Mounjaro | Tirzepatide | 204 | 44 |
| Ozempic | Semaglutide | 134 | 36 |
| Trulicity | Dulaglutide | 87 | 24 |
| Metformin Hcl Er | Metformin Hcl | 59 | 28 |
| Methimazole | Methimazole | 58 | 25 |
| Synthroid | Levothyroxine Sodium | 56 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 15 |
| Forteo | Teriparatide | 50 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 50 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 22 |
| Alendronate Sodium | Alendronate Sodium | 45 | 16 |
| Metformin Hcl | Metformin Hcl | 45 | 17 |
| Novolog Flexpen | Insulin Aspart | 45 | 20 |
| Teriparatide | Teriparatide | 44 | suppressed |
| Calcitriol | Calcitriol | 39 | 13 |
| Hydrocortisone | Hydrocortisone | 37 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 27 | 11 |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 21 | suppressed |
| Tymlos | Abaloparatide | 21 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Prednisone | Prednisone | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35,869.78 · 63 records | Amgen Inc. | CRYSVITA, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, Ozempic, PROLIA, Rybelsus, TEPEZZA, TWIIST, Tymlos, Yorvipath | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error